{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T15:28:34Z","timestamp":1773674914495,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2018,6,1]],"date-time":"2018-06-01T00:00:00Z","timestamp":1527811200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1016\/j.biopha.2018.03.065","type":"journal-article","created":{"date-parts":[[2018,3,22]],"date-time":"2018-03-22T11:15:20Z","timestamp":1521717320000},"page":"309-316","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Enhanced lipoxygenase\/LTD4 signaling accounts for the exaggerated hypertensive and nephrotoxic effects of cyclosporine plus indomethacin in rats"],"prefix":"10.1016","volume":"102","author":[{"given":"Maged W.","family":"Helmy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai M.","family":"Helmy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud M.","family":"El-Mas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2018.03.065_bib0005","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1399-0012.2005.00357.x","article-title":"Endothelin-1 plasma levels and hypertension in cyclosporine-treated renal transplant patients","volume":"19","author":"Cauduro","year":"2005","journal-title":"Clin. Transpl."},{"key":"10.1016\/j.biopha.2018.03.065_bib0010","first-page":"441","article-title":"Pharmacovigilance of calcineurin inhibitor in peidatric kidney and liver transplantation","volume":"37","author":"Riva","year":"2013","journal-title":"Farm. Hosp."},{"key":"10.1016\/j.biopha.2018.03.065_bib0015","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1034\/j.1600-6143.2002.20902.x","article-title":"Cardiovascular toxicities of immunosuppressive agents","volume":"2","author":"Miller","year":"2002","journal-title":"Am. J. Transpl."},{"key":"10.1016\/j.biopha.2018.03.065_bib0020","article-title":"Cyclosporine: a review","volume":"2012","author":"Tedesco","year":"2012","journal-title":"J. Transpl."},{"key":"10.1016\/j.biopha.2018.03.065_bib0025","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S0895-7061(00)00288-0","article-title":"Calcineurin inhibitors cause renal afferent activation in rats: a novel mechanism of cyclosporine-induced hypertension","volume":"13","author":"Zhang","year":"2000","journal-title":"Am. J. Hypertens."},{"key":"10.1016\/j.biopha.2018.03.065_bib0030","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1161\/01.HYP.0000085195.38870.44","article-title":"Role of angiotensin II and reactive oxygen species in cyclosporine A-dependent hypertension","volume":"42","author":"Nishiyama","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.biopha.2018.03.065_bib0035","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejphar.2014.05.046","article-title":"Endothelin ETA receptor antagonism in cardiovascular disease","volume":"737","author":"Nasser","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2018.03.065_bib0040","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1139\/y02-084","article-title":"Cyclosporine attenuates the autonomic modulation of reflex chronotropic responses in conscious rats","volume":"80","author":"El-Mas","year":"2002","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"10.1016\/j.biopha.2018.03.065_bib0045","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejphar.2012.08.021","article-title":"Redox imbalances incite the hypertensive, baroreflex, and autonomic effects of cyclosporine in rats","volume":"694","author":"El-Mas","year":"2012","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2018.03.065_bib0050","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0014-2999(03)01720-5","article-title":"Testosterone depletion contributes to cyclosporine-induced chronic impairment of acetylcholine renovascular relaxations","volume":"468","author":"El-Mas","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2018.03.065_bib0055","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.ejphar.2014.01.034","article-title":"Blockade of endothelin ETA, but not thromboxane, receptors offsets the cyclosporine-evoked hypertension and interrelated baroreflex and vascular dysfunctions","volume":"727","author":"Nasser","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2018.03.065_bib0060","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1016\/j.neuropharm.2011.12.017","article-title":"Crosstalk between central pathways of nitric oxide and carbon monoxide in the hypertensive action of cyclosporine","volume":"62","author":"El-Mas","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopha.2018.03.065_bib0065","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1373\/clinchem.2011.167296","article-title":"Molecular diagnostics of calcineurin-related pathologies","volume":"58","author":"Musson","year":"2012","journal-title":"Clin. Chem."},{"key":"10.1016\/j.biopha.2018.03.065_bib0070","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/rheumatology\/40.8.907","article-title":"Efficacy and safety profile of cyclosporin A in the treatmentof juvenile chronic (idiopathic) arthritis. Results of a 10-year prospective study","volume":"40","author":"Gerloni","year":"2001","journal-title":"Rheumatology (Oxf.)"},{"key":"10.1016\/j.biopha.2018.03.065_bib0075","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/00005344-200208000-00003","article-title":"Cyclosporin effects on rat aorta \u03b11-adrenoceptors and their transduction mechanisms","volume":"40","author":"Tavares","year":"2002","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.biopha.2018.03.065_bib0080","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejphar.2017.04.016","article-title":"Modulation by NADPH oxidase of the chronic cardiovascular and autonomic interaction between cyclosporine and NSAIDs in female rats","volume":"806","author":"El-Yazbi","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2018.03.065_bib0085","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1111\/bcpt.12754","article-title":"Opposite modulatory effects of selective and non-selective cyclooxygenase inhibition on cardiovascular and autonomic consequences of cyclosporine in female rats","volume":"120","author":"Ibrahim","year":"2017","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.biopha.2018.03.065_bib0090","first-page":"141","article-title":"Interaction of cyclosporine and indomethacin in the rat","volume":"61","author":"Williamson","year":"1988","journal-title":"Res. Commun. Chem. Pathol. Pharmacol."},{"issue":"17","key":"10.1016\/j.biopha.2018.03.065_bib0095","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1111\/bph.13199","article-title":"Endothelin ETA receptor\/lipid peroxides\/COX-2\/TGF-\u03b21 signalling underlies aggravated nephrotoxicity caused by cyclosporine plus indomethacin in rats","volume":"172","author":"Helmy","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2018.03.065_bib0100","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11010-016-2770-6","article-title":"The increased level of COX-dependent arachidonic acid metabolism in blood platelets from secondary progressive multiple sclerosis patients","volume":"420","author":"Morel","year":"2016","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.biopha.2018.03.065_bib0105","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1124\/mol.66.2.220","article-title":"Reduction of renal ischemia-reperfusion injury in 5-lipoxygenase knockout mice and by the 5-lipoxygenase inhibitor zileuton","volume":"66","author":"Patel","year":"2004","journal-title":"Mol. Pharmacol."},{"issue":"6","key":"10.1016\/j.biopha.2018.03.065_bib0110","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1046\/j.1523-1755.2000.00118.x","article-title":"A role for leukotrienes in cyclosporine nephrotoxicity","volume":"57","author":"Butterly","year":"2000","journal-title":"Kidney Int."},{"key":"10.1016\/j.biopha.2018.03.065_bib0115","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1182\/blood.V97.11.3433","article-title":"Chemotaxis and transendothelial migration of CD34(+) hematopoietic progenitor cells induced by the inflammatory mediator leukotrieneD4 are mediated by the 7-transmembrane receptor CysLT1","volume":"97","author":"Bautz","year":"2001","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.biopha.2018.03.065_bib0120","doi-asserted-by":"crossref","first-page":"e0167058","DOI":"10.1371\/journal.pone.0167058","article-title":"Pro-resolving effects of resolvin D2 in LTD4 and TNF-\u03b1 pre-treated human bronchi","volume":"11","author":"Khaddaj-Mallat","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.biopha.2018.03.065_bib0125","series-title":"Carleton\u2019s Histological Techniques","author":"Drury","year":"1980"},{"key":"10.1016\/j.biopha.2018.03.065_bib0130","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.taap.2014.01.008","article-title":"Celecoxib offsets the negative renal influences of cyclosporine via modulation of the TGF-\u03b21\/IL-2\/COX-2\/endothelin ETB receptor cascade","volume":"275","author":"El-Gowelli","year":"2014","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.biopha.2018.03.065_bib0135","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1046\/j.1523-1755.2000.00212.x","article-title":"Tempol, a membrane-permeable radical scavenger, reduces oxidant stress-mediated renal dysfunction and injury in the rat","volume":"58","author":"Chatterjee","year":"2000","journal-title":"Kidney Int."},{"key":"10.1016\/j.biopha.2018.03.065_bib0140","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.ejphar.2012.03.018","article-title":"Montelukast abrogates rhabdomyolysis-induced acute renal failure via rectifying detrimental changes in antioxidant profile and systemic cytokines and apoptotic factors production","volume":"683","author":"Helmy","year":"2012","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2018.03.065_bib0145","first-page":"886","article-title":"Effects of intensive cell phone (Philips Genic 900) use on the rat kidney tissue","volume":"10","author":"Koca","year":"2013","journal-title":"Urol. J."},{"key":"10.1016\/j.biopha.2018.03.065_bib0150","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1681\/ASN.V102264","article-title":"The leukotriene B4 receptor antagonist ONO-4057 inhibits nephrotoxic serum nephritis in WKY rats","volume":"10","author":"Suzuki","year":"1999","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.biopha.2018.03.065_bib0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.taap.2015.01.018","article-title":"Celecoxib, but not indomethacin, ameliorates the hypertensive and perivascular fibrotic actions of cyclosporine in rats: role of endothelin signaling","volume":"284","author":"El-Mas","year":"2015","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.biopha.2018.03.065_bib0160","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40620-016-0297-2","article-title":"Montelukast as an add-on treatment in steroid dependant nephrotic syndrome, randomised-controlled trial","volume":"29","author":"Zedan","year":"2016","journal-title":"J. Nephrol."},{"key":"10.1016\/j.biopha.2018.03.065_bib0165","first-page":"18","article-title":"Cytokines in sepsis: potent immunoregulators and potential therapeutic targets-an updated view","volume":"165974","author":"Schulte","year":"2013","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.biopha.2018.03.065_bib0170","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1124\/pr.114.009639","article-title":"Cytokines as therapeutic targets in rheumatoid arthritis and other inflammatory diseases","volume":"67","author":"Siebert","year":"2015","journal-title":"Pharmacol. Rev."},{"issue":"4","key":"10.1016\/j.biopha.2018.03.065_bib0175","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/FJC.0b013e31828399ae","article-title":"Leukotrienes, but not angiotensin II, are involved in the renal effects elicited by the prolonged cyclooxygenase-2 inhibition when sodium intake is low","volume":"61","author":"Salazar","year":"2013","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.biopha.2018.03.065_bib0180","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/ndt\/17.7.1159","article-title":"Strategies to safely interfere with prostanoid activity while avoiding adverse effects: could COX-2 AND COX-LOX dual inhibition be the answer?","volume":"17","author":"Gambaro","year":"2002","journal-title":"Nephrol. Dial. Transpl."},{"key":"10.1016\/j.biopha.2018.03.065_bib0185","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/sj.bjp.0707586","article-title":"Cysteinyl leukotrienes mediate the enhancing effects of indomethacin and aspirin on eosinophil production in murine bone marrow cultures","volume":"153","author":"Elsas","year":"2008","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.biopha.2018.03.065_bib0190","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ejphar.2005.12.053","article-title":"The broken balance in aspirin hypersensitivity","volume":"553","author":"Szczeklik","year":"2006","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2018.03.065_bib0195","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1046\/j.1523-1755.2003.00159.x","article-title":"Cellular responses to hypoxia after renal segmental infarction","volume":"64","author":"Rosenberger","year":"2003","journal-title":"Kidney Int."},{"key":"10.1016\/j.biopha.2018.03.065_bib0200","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1083\/jcb.201004082","article-title":"Feedback amplification of fibrosis through matrix stiffening and COX-2 suppression","volume":"190","author":"Liu","year":"2010","journal-title":"J. Cell Biol."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218304384?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332218304384?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T16:04:32Z","timestamp":1731427472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332218304384"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":40,"alternative-id":["S0753332218304384"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2018.03.065","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhanced lipoxygenase\/LTD4 signaling accounts for the exaggerated hypertensive and nephrotoxic effects of cyclosporine plus indomethacin in rats","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2018.03.065","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}